Anwendungsgebiet
Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older. The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.
In anderen Ländern
Dieselben Wirkstoffe in anderen Registern, dieselbe Marke zuerst.
Nationale Einträge
Die nationalen Register, in denen dieses EU-Arzneimittel aufgeführt ist.